SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-020699
Filing Date
2023-05-11
Accepted
2023-05-10 18:08:37
Documents
14
Period of Report
2023-05-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fdmt-20230510.htm   iXBRL 8-K 52647
2 EX-99.1 fdmt-ex99_1.htm EX-99 131427
3 GRAPHIC img216297824_0.jpg GRAPHIC 12475
  Complete submission text file 0000950170-23-020699.txt   332590

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fdmt-20230510_pre.xml EX-101.PRE 10260
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fdmt-20230510.xsd EX-101.SCH 2514
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fdmt-20230510_lab.xml EX-101.LAB 13904
8 EXTRACTED XBRL INSTANCE DOCUMENT fdmt-20230510_htm.xml XML 4890
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Filer) CIK: 0001650648 (see all company filings)

IRS No.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39782 | Film No.: 23908073
SIC: 2836 Biological Products, (No Diagnostic Substances)